Vera Therapeutics Vera logo

Investor Relations

Our Company

Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease. Vera is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant.

Symbol :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events

Contact Information

General Information
IR@veratx.com

Media Inquiries
Greig Communications, Inc.
Kathy Vincent
Tel: 310-403-8951
kathy@greigcommunications.com

Top